^
Association details:
| Biomarker: | EGFR overexpression |
|---|---|
| Cancer: | Mesothelioma |
| Drug: | serclutamab talirine (ABBV-321) (DNA replication inhibitor, EGFR-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate
Excerpt:
Efficacy of ABBV-321 in suppressing tumor growth was evaluated in PDX #1174, a malignant mesothelioma PDX tumor model (EGFR IHC score of 3+). Significant tumor growth suppression was demonstrated with ABBV-321 dosed at 0.15 mg/kg 2 every seven days ×3 compared to groups treated with either non-targeted ADC or cisplatin (Fig. 3G). These results suggest a novel therapeutic approach for treatment of malignant mesothelioma with EGFR overexpression.
DOI:
https://doi.org/10.1158/1535-7163.MCT-20-0149
